The U.S. Food and Drug Administration approved Swiss drugmaker Idorsia’s treatment for insomnia in adult patients.

Eisai Inc. announced that JAMA Network Open published results of SUNRISE 1 (Study 304), a pivotal Phase 3 head-to-head study that compared Dayvigo (lemborexant) to placebo and an active comparator in patients with insomnia disorder.

The U.S. regulatory agency approved Eisai Inc.’s Dayvigo in doses of 5 mg and 10 mg based on two late-stage studies testing the drug in patients with insomnia versus placebo for up to one month and six months.

Pear Therapeutics announced the filing of a submission to the U.S. Food and Drug Administration seeking marketing authorization for Somryst, a prescription digital therapeutic (PDT) intended for use in the treatment of adults with chronic insomnia and depression.

Eisai Co. and Purdue Pharma L.P. announced top-line results from the companies’ SUNRISE 2 Phase III clinical trial of lemborexant for sleep-wake disorders.

People who have trouble falling asleep and staying asleep may want to seek advice from a doctor and avoid long-term use of sleeping pills, medical experts advise.

People who spend less time in deep, rapid eye movement (REM) sleep may be more likely to develop dementia than individuals who get better quality rest, a recent study suggests.

206 million American adults struggling to get a good night’s rest seek out sleep management solutions to deal with conditions such as insomnia, sleep apnea, narcolepsy, and more.

After taking more than a year to sell off its insomnia medication ZolipiMist to Amherst Pharmaceuticals, NovaDel Pharma has dissolved the company.

A new study shows that certain birth control pills may impair sleep and raise the level of stress hormones in women who take them. The study examined women and girls who use combined hormonal contraceptives (CHCs) to treat acne. To ascertain the quality of subjects’ sleep, researchers used the Pittsburgh Sleep Quality Index, a questionnaire […]